Taken together, our findings indicate that caffeine prevents NLRP3 inflammasome activation and inhibits IL-1β upregulation by interfering with TLR4 receptor-mediated NF-κB and MAPK activities, resulting in the suppression of inflammation and fibrosis during NASH progression. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.